Literature DB >> 16293966

Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.

C Bassi1, D D Stocken, A Olah, H Friess, J Buckels, H Hickey, C Dervenis, J A Dunn, M Deakin, R Carter, P Ghaneh, J P Neoptolemos, M W Buchler.   

Abstract

BACKGROUND/AIMS: The influence of type of surgery and occurrence of post-operative complications on survival following adjuvant therapy for pancreatic cancer are uncertain.
METHODS: Cox proportional hazard modelling was used to investigate the influence of type of surgery and the presence of complications on survival in conjunction with clinico-pathological variables in the 550 patients of the ESPAC-1 adjuvant randomized controlled trial.
RESULTS: Standard Kausch-Whipple (KW) was performed in 282 (54%) patients, 186 (35%) had a pylorus-preserving (PP) KW, 39 (7%) had a distal pancreatectomy and 21 (4%) had a total pancreatectomy. Post-operative complications were reported in 140 (27%) patients. PP-KW patients survived longer with a median (95% CI) survival of 19.9 (17.3, 23.1) months compared to 14.8 (13.0, 16.7) for KW patients (chi(2)(LR) = 15.1, p < 0.001). KW patients were more likely however to have R1 margins (67 (24%) vs. 29 (16%), chi(2) = 4.59, p = 0.032), poorly differentiated tumours (70 (26%) vs. 19 (10%), chi(2) = 18.65, p < 0.001) and positive lymph nodes (165 (60%) vs. 81 (44%), chi(2) = 11.32, p < 0.001). Post-operative complications did not significantly affect survival. Independent prognostic factors were tumour grade, nodal status and tumour size but not type of surgery or post-operative complications. There was a survival benefit for chemotherapy irrespective of the type of surgery or post-operative complications.
CONCLUSIONS: The KW and PP-KW procedures did not significantly influence the hazard of death in the presence of tumour staging, demonstrating that ESPAC-1 surgeons showed good judgement in their choice of operation. Post-operative complications did not adversely affect the survival benefit from adjuvant chemotherapy. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16293966     DOI: 10.1159/000089771

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  17 in total

1.  Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.

Authors:  Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins
Journal:  HPB (Oxford)       Date:  2012-01-19       Impact factor: 3.647

2.  Morbidity after pancreatic resection.

Authors:  Markus W Büchler; Peter Kienle; Jörg Köninger
Journal:  Langenbecks Arch Surg       Date:  2006-12-05       Impact factor: 3.445

Review 3.  A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma.

Authors:  Markus K Diener; Hanns-Peter Knaebel; Christina Heukaufer; Gerd Antes; Markus W Büchler; Christoph M Seiler
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

Review 4.  Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal".

Authors:  Paula Ghaneh; Catrin Tudur-Smith; John P Neoptolemos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 6.  Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma.

Authors:  Felix J Hüttner; Christina Fitzmaurice; Guido Schwarzer; Christoph M Seiler; Gerd Antes; Markus W Büchler; Markus K Diener
Journal:  Cochrane Database Syst Rev       Date:  2016-02-16

7.  Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study.

Authors:  Marta Kalousová; Tomáš Krechler; Marie Jáchymová; Aleš A Kuběna; Aleš Zák; Tomáš Zima
Journal:  Tumour Biol       Date:  2012-08-10

Review 8.  Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.

Authors:  Christos Agalianos; Nikolaos Gouvas; Kleo Papaparaskeva; Christos Dervenis
Journal:  HPB (Oxford)       Date:  2016-06-03       Impact factor: 3.647

9.  Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.

Authors:  Sadaki Asari; Ippei Matsumoto; Hirochika Toyama; Makoto Shinzeki; Tadahiro Goto; Jun Ishida; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2015-06-25       Impact factor: 2.549

10.  Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma.

Authors:  Imran Bhatti; Oliver Peacock; Altaf K Awan; David Semeraro; Michael Larvin; Richard I Hall
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.